Seattle Genetics, Inc. (NASDAQ:SGEN) COO Eric Dobmeier sold 35,000 shares of Seattle Genetics stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $58.25, for a total value of $2,038,750.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Eric Dobmeier also recently made the following trade(s):

  • On Wednesday, November 15th, Eric Dobmeier sold 9,600 shares of Seattle Genetics stock. The stock was sold at an average price of $57.80, for a total value of $554,880.00.
  • On Thursday, August 31st, Eric Dobmeier sold 25,000 shares of Seattle Genetics stock. The stock was sold at an average price of $52.24, for a total value of $1,306,000.00.
  • On Monday, August 28th, Eric Dobmeier sold 5,343 shares of Seattle Genetics stock. The stock was sold at an average price of $47.89, for a total value of $255,876.27.

Seattle Genetics, Inc. (SGEN) opened at $59.79 on Monday. Seattle Genetics, Inc. has a 52-week low of $45.31 and a 52-week high of $73.91.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.23. The firm had revenue of $135.29 million during the quarter, compared to the consensus estimate of $112.76 million. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. The business’s revenue for the quarter was up 27.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.23) EPS. equities analysts expect that Seattle Genetics, Inc. will post -0.93 EPS for the current fiscal year.

WARNING: “Insider Selling: Seattle Genetics, Inc. (SGEN) COO Sells $2,038,750.00 in Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/20/insider-selling-seattle-genetics-inc-sgen-coo-sells-2038750-00-in-stock.html.

Several analysts have recently weighed in on SGEN shares. Jefferies Group LLC reissued a “buy” rating and set a $53.00 price objective on shares of Seattle Genetics in a report on Thursday, July 27th. ValuEngine lowered Seattle Genetics from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Cowen and Company reissued a “hold” rating and set a $54.00 price objective on shares of Seattle Genetics in a report on Friday, July 28th. BidaskClub lowered Seattle Genetics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Finally, Cantor Fitzgerald set a $46.00 target price on Seattle Genetics and gave the stock a “hold” rating in a research report on Wednesday, August 16th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $63.53.

Several hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC raised its position in shares of Seattle Genetics by 0.3% during the second quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock worth $1,640,000 after acquiring an additional 91 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of Seattle Genetics by 1.1% during the second quarter. Oregon Public Employees Retirement Fund now owns 18,400 shares of the biotechnology company’s stock worth $952,000 after acquiring an additional 200 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Seattle Genetics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 4,824 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 299 shares during the last quarter. Prudential Financial Inc. raised its position in shares of Seattle Genetics by 6.8% during the second quarter. Prudential Financial Inc. now owns 6,291 shares of the biotechnology company’s stock worth $325,000 after acquiring an additional 400 shares during the last quarter. Finally, Grandfield & Dodd LLC raised its position in shares of Seattle Genetics by 5.2% during the second quarter. Grandfield & Dodd LLC now owns 10,001 shares of the biotechnology company’s stock worth $517,000 after acquiring an additional 495 shares during the last quarter. Institutional investors own 96.93% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.